Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Celldex Therapeutics (CLDX) Net Margin (2016 - 2025)

Celldex Therapeutics (CLDX) has 16 years of Net Margin data on record, last reported at 67204.96% in Q4 2025.

  • For Q4 2025, Net Margin fell 6319398.0% year-over-year to 67204.96%; the TTM value through Dec 2025 reached 16748.03%, down 1449874.0%, while the annual FY2025 figure was 16748.03%, 1449874.0% down from the prior year.
  • Net Margin reached 67204.96% in Q4 2025 per CLDX's latest filing, down from 6704400.0% in the prior quarter.
  • Across five years, Net Margin topped out at 6704400.0% in Q3 2025 and bottomed at 67204.96% in Q4 2025.
  • Average Net Margin over 5 years is 325504.16%, with a median of 5016.12% recorded in 2021.
  • The widest YoY moves for Net Margin: up 670571999bps in 2025, down -6319398bps in 2025.
  • A 5-year view of Net Margin shows it stood at 6021.26% in 2021, then skyrocketed by 73bps to 1642.1% in 2022, then surged by 36bps to 1048.32% in 2023, then plummeted by -283bps to 4010.98% in 2024, then crashed by -1576bps to 67204.96% in 2025.
  • Per Business Quant database, its latest 3 readings for Net Margin were 67204.96% in Q4 2025, 6704400.0% in Q3 2025, and 7753.29% in Q2 2025.